Sentences with phrase «myeloma studies»

«One - size treatment for blood cancer probably doesn't fit all, researchers say: Most multiple myeloma studies involve people of European descent, but the disease is more likely to affect African - Americans.»

In the multiple myeloma study, normal weight is defined as a BMI of no more than 25 kg / m2, and morbidly obese is in the range of 35 to 40 kg / m2.

Not exact matches

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

To participate in the study, which concludes in July 2020, patients must be 18 years or older and have a histological - or cytological - proven diagnosis of a malignancy in the lung, breast, head and neck, genitourinary organs or ovaries or multiple myeloma.

Shares of Ligand Pharmaceuticals shed nearly 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

«Choice of medical center impacts life expectancy of multiple myeloma patients, study shows.»

In their current study, the team investigated ADAR1's role in multiple myeloma.

Due to the gaps in knowledge and the many unresolved questions, IQWiG still regards the use of certain forms of SCT for multiple myeloma to be acceptable only in the context of clinical studies.

An update search enlarged the pool of study data, but did not change the content of the conclusion of the benefit assessment of stem cell transplantation (SCT) for multiple myeloma conducted in 2012.

«These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher disease and others with precursors for myeloma.

Senior author Madhav Dhodapkar, M.D., the Arthur H. and Isabel Bunker Professor of Medicine and Immunobiology, and chief of Hematology, said the study, using tissue and blood samples from humans and mice, shows that chronic stimulation of the immune system by lipids made in the context of inflammation underlies the origins of at least a third of all myeloma cases.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

In our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explained.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.

«Although our study does not directly suggest screening for MGUS, regular check - ups can help physicians monitor whether MGUS is progressing to other disorders, including multiple myeloma.»

The study, «Lenalidomide (LEN) maintenance (MNTC) after high - dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, June 3.

«Lenalidomide maintenance following autologous stem cell transplant can now be considered a standard of care for people with multiple myeloma,» says Dr. McCarthy, senior author on the meta - analysis and Principal Investigator of the U.S. study, CALGB (Alliance) 100104.

«But our findings show that obesity can now be defined as a risk factor for developing multiple myeloma through this condition,» said the study's first author, Su - Hsin Chang, PhD, an assistant professor of surgery in the Division of Public Health Sciences at Washington University.

«There are clearly molecular differences between African - American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients,» said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

That trend is problematic considering that African - Americans — the most at - risk population for multiple myeloma — have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.

The study is the largest and most ethnically diverse genomics study of multiple myeloma to date, the researchers said.

A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.

The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.

The study follows similar investigations by Garland and colleagues of other cancers, including breast, colon, pancreas, bladder and multiple myeloma.

A study that used stored blood samples from U.S. Air Force personnel who conducted aerial herbicide spray missions of Agent Orange during the Vietnam war found a more than 2-fold increased risk of the precursor to multiple myeloma known as monoclonal gammopathy of undetermined significance (MGUS), according to an article published online by JAMA Oncology.

While the cause of MGUS and multiple myeloma (plasma cell cancer) remains largely unclear, studies have reported an elevated risk of multiple myeloma among farmers and other agricultural workers and pesticides have been thought to be the basis for these associations, according to study background.

«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»

If future studies confirm that role, the genes may become targets for therapies that block myeloma metastasis, she added.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).

The findings of multiple in vivo preclinical studies published online in Blood Advances, a Journal of the American Society of Hematology (ASH), indicate that this therapy could potentially treat multiple cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and acute myeloid leukemia (AML).

The researchers then tested the capacity of the modified cells to kill human multiple myeloma cells in laboratory studies and an animal model.

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

«This study presents a novel strategy for treating multiple myeloma, and we hope to bring it to patients as part of a phase I clinical trial as soon as possible,» Hofmeister says.

A Phase 1, First - in - Man, Multicenter, Open - Label, Two Part Dose - Escalation and Cohort Expansion Study of Single - Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

The laboratory primarily studies multiple myeloma, a cancer of plasma cells.

-- Poseida Therapeutics released very early data from a Phase 1 study of its CAR - T cell therapy for multiple myeloma.

Bluebird Bio (NASDAQ: BLUE) and Novartis (NYSE: NVS) have the most advanced CAR - T programs for myeloma, with Bluebird and partner Celgene (NASDAQ: CELG) planning a pivotal study this year.

«The surprising result was embodied by checkpoint expression in extramedullary myeloma showing that these lesions are able to reproduce their environment out of the bone,» said study co-author Alba Grifoni, PhD, from the Division of Vaccine Discovery at La Jolla Institute for Allergy and Immunology in La Jolla, California.

The combination of pomalidomide plus low - dose dexamethasone showed efficacy with high rates of disease control in relapsed or refractory multiple myeloma patients with severe renal impairment, according to the results of a phase II study.

A study led by Helena Jernberg Wiklund, Uppsala University / SciLifeLab, shows how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.

The purpose of this study is to identify the most appropriate dose of a new study drug (BAY 1251152) that may treat acute myeloid leukemia or multiple myeloma.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

GENIC has completed (or has ongoing) a series of studies to examine the interaction between environmental risk factors and susceptibility genes for non-Hodgkin lymphoma, melanoma, and multiple myeloma, as well as breast, ovarian, and prostate cancers.

CRP Levels Before Transplant Linked With Survival in Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSMyeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSmyeloma experienced a worse overall survival (OS) rate.